Skip to content
HowShorted

CytomX Therapeutics, Inc. short interest in 2023

In 2023, CytomX Therapeutics, Inc.'s disclosed short interest ran from 4.27% of shares outstanding on 13 Jan 2023 to 1.99% on 29 Dec 2023, a change of -2.28 percentage points. The year's high was 4.27% on 13 Jan 2023 and its low 1.47% on 15 Dec 2023, averaging 2.87% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.63 days on 15 Sep 2023. Full history: CytomX Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CytomX Therapeutics, Inc. in 2023

2023 in figures

Start of year
4.27% (13 Jan 2023)
End of year
1.99% (29 Dec 2023)
Change
-2.28 pp
High
4.27% (13 Jan 2023)
Low
1.47% (15 Dec 2023)
Average
2.87%
Highest days to cover
14.63 (15 Sep 2023)
SEC filings marked
8

Every report in 2023

CytomX Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.27%1.00
31 Jan 20232.43%1.00
15 Feb 20232.09%1.00
28 Feb 20231.93%1.76
15 Mar 20232.85%1.63
31 Mar 20232.43%1.2710-K filed, results (8-K)
14 Apr 20233.41%3.99
28 Apr 20233.72%6.41
15 May 20233.21%4.0910-Q filed, results (8-K)
31 May 20233.44%5.36
15 Jun 20233.59%10.58
30 Jun 20233.58%3.72
14 Jul 20234.06%8.58
31 Jul 20233.92%14.45
15 Aug 20233.07%7.2610-Q filed, results (8-K)
31 Aug 20233.25%13.25
15 Sep 20233.32%14.63
29 Sep 20232.56%13.15
13 Oct 20232.31%11.37
31 Oct 20231.88%5.28
15 Nov 20231.99%6.7710-Q filed, results (8-K)
30 Nov 20232.00%8.31
15 Dec 20231.47%4.37
29 Dec 20231.99%3.60

See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.